Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101’s initial efficacy and safety profile and broad ...

NanoVation will receive research funding and is eligible to receive up to approximately US$600 million in up-front cash and potential milestone payments, as well as tiered royalties on future product ...

JANESVILLE, WI, USA I 18, 2024 I GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody ...

PHILADELPHIA, PA, USA I 18, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older ...

– Initiation of the second component of the Phase 1 study, in adult DMD patients, expected in Q1 2025 ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids Dr. Michael Wechsler, Professor of ...

ROCKVILLE, MD, USA I September 16, 2024 I I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for ...

EAST HANOVER, NJ, USA I 17, 2024 I Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in ...

HDT bio’s Rapid-Response Roadmap for RNA vaccines (R 4) project granted a five-year subaward for $2M per year SEATTLE, WA, USA I 17, 2024 I HDT Bio Corp., a clinical-stage biopharmaceutical company ...

DANVILLE, CA, USA I September 17, 2024 I Nexilico, a pioneer in precision microbiome engineering, and Siolta Therapeutics, a leader in the development of live ...

Late-breaking oral presentation will discuss the potential of ZL-1503 as a novel treatment for moderate-to-severe atopic dermatitis and other diseases ...